Pathway Financial Advisers’s iShares Biotechnology ETF IBB Stock Holding History

Pathway Financial Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-103	Closed	-$14.7K	–	242
2025 Q3	$14.7K	Buy	+103	New	+$14.1K	﹤0.01%	313
2025 Q1	–	Sell	-102	Closed	-$13.5K	–	272
2024 Q4	$13.5K	Hold	102	–	–	﹤0.01%	334
2024 Q3	$14.9K	Hold	102	–	–	0.01%	273
2024 Q2	$14K	Hold	102	–	–	0.01%	317
2024 Q1	$14K	Hold	102	–	–	0.01%	319
2023 Q4	$13.9K	Hold	102	–	–	0.01%	327
2023 Q3	$12.5K	Buy	+102	New	+$13K	0.01%	340
2023 Q1	$13.2K	Sell	102 -75	-42%	-$9.82K	0.01%	353
2022 Q4	$23.2K	Buy	+177	New	+$22.9K	0.01%	313

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pathway Financial Advisers's IBB Position: Q4 2025 in Review

Pathway Financial Advisers sold out of iShares Biotechnology ETF (IBB) in Q4 2025, closing a stake of 103 shares — an estimated $14.7K sold.

Pathway Financial Advisers first reported a position in IBB in Q4 2022 and held it in 9 quarters. The position peaked at $23.2K in Q4 2022. 956 funds tracked by Wall St. Rank hold IBB as of Q4 2025.

Pathway Financial Advisers reported no remaining iShares Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
Pathway Financial Advisers sold 103 iShares Biotechnology ETF shares in Q4 2025, an estimated $14.7K.
Pathway Financial Advisers first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 9 quarters.
Pathway Financial Advisers's iShares Biotechnology ETF position peaked at $23.2K in Q4 2022.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2025.

Based on Pathway Financial Advisers's 13F filing for Q4 2025, filed 6 Feb 2026.